Global Oral Biologics Market By Offerings (Glucagon-like Peptide 1 (GLP-1) Receptor Agonist, Hormone, Recombinant Enzyme, Guanylate Cyclase-C Agonist, Somatostatin Analogue, Combination Drugs, Others); By Therapeutic Area (Inflammatory Bowel Disease, Diabetes, Ulcerative Colitis and Crohn Disease, Acromegaly and Neuroendocrine Tumours, Osteoporosis, Inflammatory disease, Others); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online, Others); By Region (U.S., Canada, Mexico, Rest of North America, France, UK, Spain, Germany, Italy, Nordic Countries , Benelux Union, Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Singapore, Philippines, Indonesia, Thailand, Malaysia, Vietnam, Rest of Southeast Asia), Brazil, Argentina, Rest of Latin America, Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2020 - 2028
Industry Trends
The market for medicines has been a notable driver for the healthcare industry over the years. Concerns related to various disorders had led to the development of various products that can help in medication of patients in the past. With advancements in medical sciences and chemistry, the process of development for medicines has seen a massive reduction in time. Moreover, investments towards the same have been growing over the years. Advancements have been achieved in not only the way medicines are manufactured but also in the methods these medicines can be administered to patients. Oral biologics are a noble form of medicines which are developed in order to provide optimal care to patients suffering from a wide range of diseases and disorders. Biologics are termed as medicines which include living organisms as a major constituent of the medicine. These living organisms can include peptides, and proteins, among others. The integration of these substances is undertaken in order to develop a more potent medication for the disease and help the patient in early recovery. Traditionally, biologics were administered in the injectable form but with improvements in product development, companies have been able to synthesize biologics that can be administered through the oral form. These efforts are aimed at providing lower risks to the patient and providing them with the required medication in an optimal manner. Investments towards the development of these products are seen to have grown over the years and the rapid advancements in various medical technologies are painting a positive picture for market growth over the near future.
Offering Outlook:
Market participants that are working for the development of various medicines are looking towards enhancing the capabilities of their products for improved effects against the ailments to patients. In order to boost these efforts, they have been investing on a consistent basis towards the development of new product lines or to develop an optimized form of an earlier product. This trend has also been observed for the creation of products pertaining to oral biologics market. Glucagon-Like Peptide (GLP-1) have been a key development in the market with major application for the treatment of diabetes. Rybelsus, which is a product in this category developed from Novo Nordisk A/S, was recently provided with regulatory approval from the United States Food and Drug Administration (FDA). The adoption of these products in the market are expected to be significant in terms of revenue owing to the rising prevalence of type-II diabetes across various regions. Combination drugs are observed to be a newer approach towards provision of drugs. These products utilize multiple active ingredients in the same product form for better effects on the patient’s body. The development of combination drugs in oral biologics market is seen to be limited over the years but is expected to grow in the near future.
Therapeutic Area Outlook:
Diseases have been a major hurdle for mankind over the years. The prevalence of a wide range of disorders has affected the advancements of the global markets in an adverse manner. These trends have been influential for the medical and pharmaceutical sector’s operations. Companies in the sector have been proactive in terms of their investments to support the care provision and prevention measures for various diseases. Oral biologics have been developed majorly to tackle disorders in the inflammatory and autoimmune types, among others. Diabetes has been a major form of disease that has affected a wide population base on the global scale. Also, rheumatoid arthritis has been a notable joint disorder which has affected patients across various age groups over the years. Development initiatives for oral biologics that would help in the treatment of these disorders have led to some products being launched in the market. These products are now available to the general public while a pipeline of products is under trials and are awaiting approval from regulatory organizations. The adoption of these products is expected to grow with better marketing and supply chain activities thereby helping the growth of the overall oral biologics market.
Distribution Channel Outlook:
The healthcare sector is seen to be dependent on various processes that help in providing their products to the users. These processes include sourcing of raw materials for products, manufacturing and production processes, packaging processes and supply chain operations. The processes in the supply chain are vital since these processes play the role of a bridge between manufacturers/distributors and the various end users in the market. The notable channels for product distribution used in the oral biologics market include pharmacies in hospitals and retail pharmacies as well. Hospitals have been a key component in the healthcare supply chain with private and public entities focusing on the medicine distribution departments for better care provision for in-house and out-patient services. The widespread network of hospitals across various countries is considered beneficial for medicine provision and is hence the highest revenue contributor to the market in the recent scenario. The growing prevalence of online modes for the procurement of various products has trickled into the healthcare sector. Various companies are now providing oral biologics to customers’ residences and allowing them to book their medicines through online portals. This trend has been key in the distribution of medicines over the period of lockdowns due to the outbreak of the novel coronavirus (COVID-19). More number of people have now become familiar to buy oral biologics through online modes and the growth for the same is expected to increase in the near future.
Region Outlook:
The market for medicines has been observed to be a major revenue generator in the Western countries. The regions of North America and Europe have been among the notable areas for investments and sales of various market offerings. In the case of oral biologics market, the development of most market offerings has been observed to be in the countries across the aforementioned regions. This has led to a significant share creation for market revenue among the countries situated in the region of North America. The presence of notable market participants in the region has also been a key factor for influencing the awareness regarding market offerings across the region. Furthermore, countries in the region of Asia Pacific are seen to consist of a population that has been suffering from numerous medical disorders. The prevalence of diseases related to autoimmune system, orthopaedics and the cardiovascular systems has been growing over the years owing to various factors including changing lifestyles of people, and pollution, among others. Governing authorities have been working with medicine manufacturers in order to create a network of curative measures for numerous diseases. The adoption of oral biologics is expected to play a key role in these efforts. The advantages of oral biologics over traditional medicinal methods are thought to aid the growth of adoption for market offerings in the region. Also, the adoption rate is expected to grow at a significant rate which can help in improving the growth rate of market revenue across the region. These factors are expected to propel the oral biologics market towards growth over the forecast period.
The global oral biologics market was estimated to be US$ 1103.62 Mn in 2019 and is expected to grow at a CAGR of 15.9% during the forecast period (2020 – 2028).
Global Oral Biologics Market Revenue & Forecast, (US$ Million), 2015 – 2027
Competitive Landscape
The report provides both, qualitative and quantitative research of oral biologics market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analyzed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the players operating in the oral biologics market are AbbVie Inc., Allena Pharmaceuticals, Inc., Eli Lilly and Company, Gilead Sciences, Inc., McKesson Corporation, Novo Nordisk A/S, Intertek Group plc, Pfizer Inc., Rani Therapeutics, and Veloce Digital Health among others.
Global Oral Biologics Market:
- By Offering
- Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
- Hormone
- Recombinant Enzyme
- Guanylate Cyclase-C Agonist
- Somatostatin Analogue
- Combination Drugs
- Others
- By Therapeutic Area
- Inflammatory Bowel Disease
- Diabetes
- Ulcerative Colitis and Crohn Disease
- Acromegaly and Neuroendocrine Tumours
- Osteoporosis
- Inflammatory disease
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online
- Others
- By Region:
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- North America
Table of Contents
1. Market
Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2015 - 2018
1.2.2. Base
Year: 2019
1.2.3. Forecast
Years: 2020 – 2028
2. Key Target
Audiences
3. Research
Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations
and Insights from AMI’s Perspective**
5. Holistic
Overview of Oral Biologics Market
6. Market
Synopsis: Oral Biologics Market
7. Oral
Biologics Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
Oral Biologics Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Oral Biologics Market
7.6. Porter’s Five Force Analysis
7.7. Impact of
Covid-19 on Oral Biologics Market
8. Global Oral
Biologics Market Analysis and Forecasts, 2020 – 2028
8.1. Overview
8.1.1. Global
Oral Biologics Market Revenue (US$ Mn)
8.2. Global
Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Offering
8.2.1. Glucagon-like
Peptide 1 (GLP-1) Receptor Agonist
8.2.1.1. Definition
8.2.1.2. Market
Estimation and Penetration, 2015 – 2019
8.2.1.3. Market
Forecast, 2020 – 2028
8.2.1.4. Compound
Annual Growth Rate (CAGR)
8.2.1.5. Regional
Bifurcation
8.2.1.5.1. North
America
8.2.1.5.1.1. Market
Estimation, 2015 – 2019
8.2.1.5.1.2. Market
Forecast, 2020 – 2028
8.2.1.5.2. Europe
8.2.1.5.2.1. Market
Estimation, 2015 – 2019
8.2.1.5.2.2. Market
Forecast, 2020 – 2028
8.2.1.5.3. Asia
Pacific
8.2.1.5.3.1. Market
Estimation, 2015 – 2019
8.2.1.5.3.2. Market
Forecast, 2020 – 2028
8.2.1.5.4. Middle
East and Africa
8.2.1.5.4.1. Market
Estimation, 2015 – 2019
8.2.1.5.4.2. Market
Forecast, 2020 – 2028
8.2.1.5.5. Latin
America
8.2.1.5.5.1. Market
Estimation, 2015 – 2019
8.2.1.5.5.2. Market
Forecast, 2020 – 2028
8.2.2. Hormone
8.2.2.1. Definition
8.2.2.2. Market
Estimation and Penetration, 2015 – 2019
8.2.2.3. Market
Forecast, 2020 – 2028
8.2.2.4. Compound
Annual Growth Rate (CAGR)
8.2.2.5. Regional
Bifurcation
8.2.2.5.1. North
America
8.2.2.5.1.1. Market
Estimation, 2015 – 2019
8.2.2.5.1.2. Market
Forecast, 2020 – 2028
8.2.2.5.2. Europe
8.2.2.5.2.1. Market
Estimation, 2015 – 2019
8.2.2.5.2.2. Market
Forecast, 2020 – 2028
8.2.2.5.3. Asia
Pacific
8.2.2.5.3.1. Market
Estimation, 2015 – 2019
8.2.2.5.3.2. Market
Forecast, 2020 – 2028
8.2.2.5.4. Middle
East and Africa
8.2.2.5.4.1. Market
Estimation, 2015 – 2019
8.2.2.5.4.2. Market
Forecast, 2020 – 2028
8.2.2.5.5. Latin
America
8.2.2.5.5.1. Market
Estimation, 2015 – 2019
8.2.2.5.5.2. Market
Forecast, 2020 – 2028
8.2.3. Recombinant
Enzyme
8.2.3.1. Definition
8.2.3.2. Market
Estimation and Penetration, 2015 – 2019
8.2.3.3. Market
Forecast, 2020 – 2028
8.2.3.4. Compound
Annual Growth Rate (CAGR)
8.2.3.5. Regional
Bifurcation
8.2.3.5.1. North
America
8.2.3.5.1.1. Market
Estimation, 2015 – 2019
8.2.3.5.1.2. Market
Forecast, 2020 – 2028
8.2.3.5.2. Europe
8.2.3.5.2.1. Market
Estimation, 2015 – 2019
8.2.3.5.2.2. Market
Forecast, 2020 – 2028
8.2.3.5.3. Asia
Pacific
8.2.3.5.3.1. Market
Estimation, 2015 – 2019
8.2.3.5.3.2. Market
Forecast, 2020 – 2028
8.2.3.5.4. Middle
East and Africa
8.2.3.5.4.1. Market
Estimation, 2015 – 2019
8.2.3.5.4.2. Market
Forecast, 2020 – 2028
8.2.3.5.5. Latin
America
8.2.3.5.5.1. Market
Estimation, 2015 – 2019
8.2.3.5.5.2. Market
Forecast, 2020 – 2028
8.2.4. Guanylate
Cyclase-C Agonist
8.2.4.1. Definition
8.2.4.2. Market
Estimation and Penetration, 2015 – 2019
8.2.4.3. Market
Forecast, 2020 – 2028
8.2.4.4. Compound
Annual Growth Rate (CAGR)
8.2.4.5. Regional
Bifurcation
8.2.4.5.1. North
America
8.2.4.5.1.1. Market
Estimation, 2015 – 2019
8.2.4.5.1.2. Market
Forecast, 2020 – 2028
8.2.4.5.2. Europe
8.2.4.5.2.1. Market
Estimation, 2015 – 2019
8.2.4.5.2.2. Market
Forecast, 2020 – 2028
8.2.4.5.3. Asia
Pacific
8.2.4.5.3.1. Market
Estimation, 2015 – 2019
8.2.4.5.3.2. Market
Forecast, 2020 – 2028
8.2.4.5.4. Middle
East and Africa
8.2.4.5.4.1. Market
Estimation, 2015 – 2019
8.2.4.5.4.2. Market
Forecast, 2020 – 2028
8.2.4.5.5. Latin
America
8.2.4.5.5.1. Market
Estimation, 2015 – 2019
8.2.4.5.5.2. Market
Forecast, 2020 – 2028
8.2.5. Somatostatin
Analogue
8.2.5.1. Definition
8.2.5.2. Market
Estimation and Penetration, 2015 – 2019
8.2.5.3. Market
Forecast, 2020 – 2028
8.2.5.4. Compound
Annual Growth Rate (CAGR)
8.2.5.5. Regional
Bifurcation
8.2.5.5.1. North
America
8.2.5.5.1.1. Market
Estimation, 2015 – 2019
8.2.5.5.1.2. Market
Forecast, 2020 – 2028
8.2.5.5.2. Europe
8.2.5.5.2.1. Market
Estimation, 2015 – 2019
8.2.5.5.2.2. Market
Forecast, 2020 – 2028
8.2.5.5.3. Asia
Pacific
8.2.5.5.3.1. Market
Estimation, 2015 – 2019
8.2.5.5.3.2. Market
Forecast, 2020 – 2028
8.2.5.5.4. Middle
East and Africa
8.2.5.5.4.1. Market
Estimation, 2015 – 2019
8.2.5.5.4.2. Market
Forecast, 2020 – 2028
8.2.5.5.5. Latin
America
8.2.5.5.5.1. Market
Estimation, 2015 – 2019
8.2.5.5.5.2. Market
Forecast, 2020 – 2028
8.2.6. Combination
Drugs
8.2.6.1. Definition
8.2.6.2. Market
Estimation and Penetration, 2015 – 2019
8.2.6.3. Market
Forecast, 2020 – 2028
8.2.6.4. Compound
Annual Growth Rate (CAGR)
8.2.6.5. Regional
Bifurcation
8.2.6.5.1. North
America
8.2.6.5.1.1. Market
Estimation, 2015 – 2019
8.2.6.5.1.2. Market
Forecast, 2020 – 2028
8.2.6.5.2. Europe
8.2.6.5.2.1. Market
Estimation, 2015 – 2019
8.2.6.5.2.2. Market
Forecast, 2020 – 2028
8.2.6.5.3. Asia
Pacific
8.2.6.5.3.1. Market
Estimation, 2015 – 2019
8.2.6.5.3.2. Market
Forecast, 2020 – 2028
8.2.6.5.4. Middle
East and Africa
8.2.6.5.4.1. Market
Estimation, 2015 – 2019
8.2.6.5.4.2. Market
Forecast, 2020 – 2028
8.2.6.5.5. Latin
America
8.2.6.5.5.1. Market
Estimation, 2015 – 2019
8.2.6.5.5.2. Market
Forecast, 2020 – 2028
8.2.7. Others
8.2.7.1. Definition
8.2.7.2. Market
Estimation and Penetration, 2015 – 2019
8.2.7.3. Market
Forecast, 2020 – 2028
8.2.7.4. Compound
Annual Growth Rate (CAGR)
8.2.7.5. Regional
Bifurcation
8.2.7.5.1. North
America
8.2.7.5.1.1. Market
Estimation, 2015 – 2019
8.2.7.5.1.2. Market
Forecast, 2020 – 2028
8.2.7.5.2. Europe
8.2.7.5.2.1. Market
Estimation, 2015 – 2019
8.2.7.5.2.2. Market
Forecast, 2020 – 2028
8.2.7.5.3. Asia
Pacific
8.2.7.5.3.1. Market
Estimation, 2015 – 2019
8.2.7.5.3.2. Market
Forecast, 2020 – 2028
8.2.7.5.4. Middle
East and Africa
8.2.7.5.4.1. Market
Estimation, 2015 – 2019
8.2.7.5.4.2. Market
Forecast, 2020 – 2028
8.2.7.5.5. Latin
America
8.2.7.5.5.1. Market
Estimation, 2015 – 2019
8.2.7.5.5.2. Market
Forecast, 2020 – 2028
8.3. Key
Segment for Channeling Investments
8.3.1. By
Offering
9. Global Oral
Biologics Market Analysis and Forecasts, 2020 – 2028
9.1. Overview
9.2. Global
Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
9.2.1. Inflammatory
bowel disease
9.2.1.1. Definition
9.2.1.2. Market
Estimation and Penetration, 2015 – 2019
9.2.1.3. Market
Forecast, 2020 – 2028
9.2.1.4. Compound
Annual Growth Rate (CAGR)
9.2.1.5. Regional
Bifurcation
9.2.1.5.1. North
America
9.2.1.5.1.1. Market
Estimation, 2015 – 2019
9.2.1.5.1.2. Market
Forecast, 2020 – 2028
9.2.1.5.2. Europe
9.2.1.5.2.1. Market
Estimation, 2015 – 2019
9.2.1.5.2.2. Market
Forecast, 2020 – 2028
9.2.1.5.3. Asia
Pacific
9.2.1.5.3.1. Market
Estimation, 2015 – 2019
9.2.1.5.3.2. Market
Forecast, 2020 – 2028
9.2.1.5.4. Middle
East and Africa
9.2.1.5.4.1. Market
Estimation, 2015 – 2019
9.2.1.5.4.2. Market
Forecast, 2020 – 2028
9.2.1.5.5. Latin
America
9.2.1.5.5.1. Market
Estimation, 2015 – 2019
9.2.1.5.5.2. Market
Forecast, 2020 – 2028
9.2.2. Diabetes
9.2.2.1. Definition
9.2.2.2. Market
Estimation and Penetration, 2015 – 2019
9.2.2.3. Market
Forecast, 2020 – 2028
9.2.2.4. Compound
Annual Growth Rate (CAGR)
9.2.2.5. Regional
Bifurcation
9.2.2.5.1. North
America
9.2.2.5.1.1. Market
Estimation, 2015 – 2019
9.2.2.5.1.2. Market
Forecast, 2020 – 2028
9.2.2.5.2. Europe
9.2.2.5.2.1. Market
Estimation, 2015 – 2019
9.2.2.5.2.2. Market
Forecast, 2020 – 2028
9.2.2.5.3. Asia
Pacific
9.2.2.5.3.1. Market
Estimation, 2015 – 2019
9.2.2.5.3.2. Market
Forecast, 2020 – 2028
9.2.2.5.4. Middle
East and Africa
9.2.2.5.4.1. Market
Estimation, 2015 – 2019
9.2.2.5.4.2. Market
Forecast, 2020 – 2028
9.2.2.5.5. Latin
America
9.2.2.5.5.1. Market
Estimation, 2015 – 2019
9.2.2.5.5.2. Market
Forecast, 2020 – 2028
9.2.3. Ulcerative
colitis and Crohn disease
9.2.3.1. Definition
9.2.3.2. Market
Estimation and Penetration, 2015 – 2019
9.2.3.3. Market
Forecast, 2020 – 2028
9.2.3.4. Compound
Annual Growth Rate (CAGR)
9.2.3.5. Regional
Bifurcation
9.2.3.5.1. North
America
9.2.3.5.1.1. Market
Estimation, 2015 – 2019
9.2.3.5.1.2. Market
Forecast, 2020 – 2028
9.2.3.5.2. Europe
9.2.3.5.2.1. Market
Estimation, 2015 – 2019
9.2.3.5.2.2. Market
Forecast, 2020 – 2028
9.2.3.5.3. Asia
Pacific
9.2.3.5.3.1. Market
Estimation, 2015 – 2019
9.2.3.5.3.2. Market
Forecast, 2020 – 2028
9.2.3.5.4. Middle
East and Africa
9.2.3.5.4.1. Market
Estimation, 2015 – 2019
9.2.3.5.4.2. Market
Forecast, 2020 – 2028
9.2.3.5.5. Latin
America
9.2.3.5.5.1. Market
Estimation, 2015 – 2019
9.2.3.5.5.2. Market
Forecast, 2020 – 2028
9.2.4. Acromegaly
and neuroendocrine tumors
9.2.4.1. Definition
9.2.4.2. Market
Estimation and Penetration, 2015 – 2019
9.2.4.3. Market
Forecast, 2020 – 2028
9.2.4.4. Compound
Annual Growth Rate (CAGR)
9.2.4.5. Regional
Bifurcation
9.2.4.5.1. North
America
9.2.4.5.1.1. Market
Estimation, 2015 – 2019
9.2.4.5.1.2. Market
Forecast, 2020 – 2028
9.2.4.5.2. Europe
9.2.4.5.2.1. Market
Estimation, 2015 – 2019
9.2.4.5.2.2. Market
Forecast, 2020 – 2028
9.2.4.5.3. Asia
Pacific
9.2.4.5.3.1. Market
Estimation, 2015 – 2019
9.2.4.5.3.2. Market
Forecast, 2020 – 2028
9.2.4.5.4. Middle
East and Africa
9.2.4.5.4.1. Market
Estimation, 2015 – 2019
9.2.4.5.4.2. Market
Forecast, 2020 – 2028
9.2.4.5.5. Latin
America
9.2.4.5.5.1. Market
Estimation, 2015 – 2019
9.2.4.5.5.2. Market
Forecast, 2020 – 2028
9.2.5. Osteoporosis
9.2.5.1. Definition
9.2.5.2. Market
Estimation and Penetration, 2015 – 2019
9.2.5.3. Market
Forecast, 2020 – 2028
9.2.5.4. Compound
Annual Growth Rate (CAGR)
9.2.5.5. Regional
Bifurcation
9.2.5.5.1. North
America
9.2.5.5.1.1. Market
Estimation, 2015 – 2019
9.2.5.5.1.2. Market
Forecast, 2020 – 2028
9.2.5.5.2. Europe
9.2.5.5.2.1. Market
Estimation, 2015 – 2019
9.2.5.5.2.2. Market
Forecast, 2020 – 2028
9.2.5.5.3. Asia
Pacific
9.2.5.5.3.1. Market
Estimation, 2015 – 2019
9.2.5.5.3.2. Market
Forecast, 2020 – 2028
9.2.5.5.4. Middle
East and Africa
9.2.5.5.4.1. Market
Estimation, 2015 – 2019
9.2.5.5.4.2. Market
Forecast, 2020 – 2028
9.2.5.5.5. Latin
America
9.2.5.5.5.1. Market
Estimation, 2015 – 2019
9.2.5.5.5.2. Market
Forecast, 2020 – 2028
9.2.6. Inflammatory
disease
9.2.6.1. Definition
9.2.6.2. Market
Estimation and Penetration, 2015 – 2019
9.2.6.3. Market
Forecast, 2020 – 2028
9.2.6.4. Compound
Annual Growth Rate (CAGR)
9.2.6.5. Regional
Bifurcation
9.2.6.5.1. North
America
9.2.6.5.1.1. Market
Estimation, 2015 – 2019
9.2.6.5.1.2. Market
Forecast, 2020 – 2028
9.2.6.5.2. Europe
9.2.6.5.2.1. Market
Estimation, 2015 – 2019
9.2.6.5.2.2. Market
Forecast, 2020 – 2028
9.2.6.5.3. Asia
Pacific
9.2.6.5.3.1. Market
Estimation, 2015 – 2019
9.2.6.5.3.2. Market
Forecast, 2020 – 2028
9.2.6.5.4. Middle
East and Africa
9.2.6.5.4.1. Market
Estimation, 2015 – 2019
9.2.6.5.4.2. Market
Forecast, 2020 – 2028
9.2.6.5.5. Latin
America
9.2.6.5.5.1. Market
Estimation, 2015 – 2019
9.2.6.5.5.2. Market
Forecast, 2020 – 2028
9.2.7. Others
9.2.7.1. Definition
9.2.7.2. Market
Estimation and Penetration, 2015 – 2019
9.2.7.3. Market
Forecast, 2020 – 2028
9.2.7.4. Compound
Annual Growth Rate (CAGR)
9.2.7.5. Regional
Bifurcation
9.2.7.5.1. North
America
9.2.7.5.1.1. Market
Estimation, 2015 – 2019
9.2.7.5.1.2. Market
Forecast, 2020 – 2028
9.2.7.5.2. Europe
9.2.7.5.2.1. Market
Estimation, 2015 – 2019
9.2.7.5.2.2. Market
Forecast, 2020 – 2028
9.2.7.5.3. Asia
Pacific
9.2.7.5.3.1. Market
Estimation, 2015 – 2019
9.2.7.5.3.2. Market
Forecast, 2020 – 2028
9.2.7.5.4. Middle
East and Africa
9.2.7.5.4.1. Market
Estimation, 2015 – 2019
9.2.7.5.4.2. Market
Forecast, 2020 – 2028
9.2.7.5.5. Latin
America
9.2.7.5.5.1. Market
Estimation, 2015 – 2019
9.2.7.5.5.2. Market
Forecast, 2020 – 2028
9.3. Key
Segment for Channeling Investments
9.3.1. By Therapeutic
Area
10. Global
Oral Biologics Market Analysis and Forecasts, 2020 – 2028
10.1. Overview
10.2. Global
Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
10.2.1. Hospital
Pharmacies
10.2.1.1. Definition
10.2.1.2. Market
Estimation and Penetration, 2015 – 2019
10.2.1.3. Market
Forecast, 2020 – 2028
10.2.1.4. Compound
Annual Growth Rate (CAGR)
10.2.1.5. Regional
Bifurcation
10.2.1.5.1. North
America
10.2.1.5.1.1. Market
Estimation, 2015 – 2019
10.2.1.5.1.2. Market
Forecast, 2020 – 2028
10.2.1.5.2. Europe
10.2.1.5.2.1. Market
Estimation, 2015 – 2019
10.2.1.5.2.2. Market
Forecast, 2020 – 2028
10.2.1.5.3. Asia
Pacific
10.2.1.5.3.1. Market
Estimation, 2015 – 2019
10.2.1.5.3.2. Market
Forecast, 2020 – 2028
10.2.1.5.4. Middle
East and Africa
10.2.1.5.4.1. Market
Estimation, 2015 – 2019
10.2.1.5.4.2. Market
Forecast, 2020 – 2028
10.2.1.5.5. Latin
America
10.2.1.5.5.1. Market
Estimation, 2015 – 2019
10.2.1.5.5.2. Market
Forecast, 2020 – 2028
10.2.2. Retail
Pharmacies
10.2.2.1. Definition
10.2.2.2. Market
Estimation and Penetration, 2015 – 2019
10.2.2.3. Market
Forecast, 2020 – 2028
10.2.2.4. Compound
Annual Growth Rate (CAGR)
10.2.2.5. Regional
Bifurcation
10.2.2.5.1. North
America
10.2.2.5.1.1. Market
Estimation, 2015 – 2019
10.2.2.5.1.2. Market
Forecast, 2020 – 2028
10.2.2.5.2. Europe
10.2.2.5.2.1. Market
Estimation, 2015 – 2019
10.2.2.5.2.2. Market
Forecast, 2020 – 2028
10.2.2.5.3. Asia
Pacific
10.2.2.5.3.1. Market
Estimation, 2015 – 2019
10.2.2.5.3.2. Market
Forecast, 2020 – 2028
10.2.2.5.4. Middle
East and Africa
10.2.2.5.4.1. Market
Estimation, 2015 – 2019
10.2.2.5.4.2. Market
Forecast, 2020 – 2028
10.2.2.5.5. Latin
America
10.2.2.5.5.1. Market
Estimation, 2015 – 2019
10.2.2.5.5.2. Market
Forecast, 2020 – 2028
10.2.3. Online
10.2.3.1. Definition
10.2.3.2. Market
Estimation and Penetration, 2015 – 2019
10.2.3.3. Market
Forecast, 2020 – 2028
10.2.3.4. Compound
Annual Growth Rate (CAGR)
10.2.3.5. Regional
Bifurcation
10.2.3.5.1. North
America
10.2.3.5.1.1. Market
Estimation, 2015 – 2019
10.2.3.5.1.2. Market
Forecast, 2020 – 2028
10.2.3.5.2. Europe
10.2.3.5.2.1. Market
Estimation, 2015 – 2019
10.2.3.5.2.2. Market
Forecast, 2020 – 2028
10.2.3.5.3. Asia
Pacific
10.2.3.5.3.1. Market
Estimation, 2015 – 2019
10.2.3.5.3.2. Market
Forecast, 2020 – 2028
10.2.3.5.4. Middle
East and Africa
10.2.3.5.4.1. Market
Estimation, 2015 – 2019
10.2.3.5.4.2. Market
Forecast, 2020 – 2028
10.2.3.5.5. Latin
America
10.2.3.5.5.1. Market
Estimation, 2015 – 2019
10.2.3.5.5.2. Market
Forecast, 2020 – 2028
10.2.4. Others
10.2.4.1. Definition
10.2.4.2. Market
Estimation and Penetration, 2015 – 2019
10.2.4.3. Market
Forecast, 2020 – 2028
10.2.4.4. Compound
Annual Growth Rate (CAGR)
10.2.4.5. Regional
Bifurcation
10.2.4.5.1. North
America
10.2.4.5.1.1. Market
Estimation, 2015 – 2019
10.2.4.5.1.2. Market
Forecast, 2020 – 2028
10.2.4.5.2. Europe
10.2.4.5.2.1. Market
Estimation, 2015 – 2019
10.2.4.5.2.2. Market
Forecast, 2020 – 2028
10.2.4.5.3. Asia
Pacific
10.2.4.5.3.1. Market
Estimation, 2015 – 2019
10.2.4.5.3.2. Market
Forecast, 2020 – 2028
10.2.4.5.4. Middle
East and Africa
10.2.4.5.4.1. Market
Estimation, 2015 – 2019
10.2.4.5.4.2. Market
Forecast, 2020 – 2028
10.2.4.5.5. Latin
America
10.2.4.5.5.1. Market
Estimation, 2015 – 2019
10.2.4.5.5.2. Market
Forecast, 2020 – 2028
10.3. Key
Segment for Channeling Investments
10.3.1. By
Distribution Channel
11. North
America Oral Biologics Market Analysis and Forecasts, 2020 - 2028
11.1. Overview
11.1.1. North
America Oral Biologics Market Revenue (US$ Mn)
11.2. North
America Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Offering
11.2.1. Glucagon-like
Peptide 1 (GLP-1) Receptor Agonist
11.2.2. Hormone
11.2.3. Recombinant
Enzyme
11.2.4. Guanylate
Cyclase-C Agonist
11.2.5. Somatostatin
Analogue
11.2.6. Combination
Drugs
11.2.7. Others
11.3. North
America Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Therapeutic
Area
11.3.1. Inflammatory
bowel disease
11.3.2. Diabetes
11.3.3. Ulcerative
colitis and Crohn disease
11.3.4. Acromegaly
and neuroendocrine tumors
11.3.5. Osteoporosis
11.3.6. Inflammatory
disease
11.3.7. Others
11.4. North
America Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
11.4.1. Hospital
Pharmacies
11.4.2. Retail
Pharmacies
11.4.3. Online
11.4.4. Others
11.5. North
America Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Country
11.5.1. U.S
11.5.1.1. U.S
Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Offering
11.5.1.1.1. Glucagon-like
Peptide 1 (GLP-1) Receptor Agonist
11.5.1.1.2. Hormone
11.5.1.1.3. Recombinant
Enzyme
11.5.1.1.4. Guanylate
Cyclase-C Agonist
11.5.1.1.5. Somatostatin
Analogue
11.5.1.1.6. Combination
Drugs
11.5.1.1.7. Others
11.5.1.2. U.S
Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
11.5.1.2.1. Inflammatory
bowel disease
11.5.1.2.2. Diabetes
11.5.1.2.3. Ulcerative
colitis and Crohn disease
11.5.1.2.4. Acromegaly
and neuroendocrine tumors
11.5.1.2.5. Osteoporosis
11.5.1.2.6. Inflammatory
disease
11.5.1.2.7. Others
11.5.1.3. U.S
Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
11.5.1.3.1. Hospital
Pharmacies
11.5.1.3.2. Retail
Pharmacies
11.5.1.3.3. Online
11.5.1.3.4. Others
11.5.2. Canada
11.5.2.1. Canada
Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Offering
11.5.2.1.1. Glucagon-like
Peptide 1 (GLP-1) Receptor Agonist
11.5.2.1.2. Hormone
11.5.2.1.3. Recombinant
Enzyme
11.5.2.1.4. Guanylate
Cyclase-C Agonist
11.5.2.1.5. Somatostatin
Analogue
11.5.2.1.6. Combination
Drugs
11.5.2.1.7. Others
11.5.2.2. Canada
Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
11.5.2.2.1. Inflammatory
bowel disease
11.5.2.2.2. Diabetes
11.5.2.2.3. Ulcerative
colitis and Crohn disease
11.5.2.2.4. Acromegaly
and neuroendocrine tumors
11.5.2.2.5. Osteoporosis
11.5.2.2.6. Inflammatory
disease
11.5.2.2.7. Others
11.5.2.3. Canada
Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
11.5.2.3.1. Hospital
Pharmacies
11.5.2.3.2. Retail
Pharmacies
11.5.2.3.3. Online
11.5.2.3.4. Others
11.5.3. Mexico
11.5.3.1. Mexico
Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Offering
11.5.3.1.1. Glucagon-like
Peptide 1 (GLP-1) Receptor Agonist
11.5.3.1.2. Hormone
11.5.3.1.3. Recombinant
Enzyme
11.5.3.1.4. Guanylate
Cyclase-C Agonist
11.5.3.1.5. Somatostatin
Analogue
11.5.3.1.6. Combination
Drugs
11.5.3.1.7. Others
11.5.3.2. Mexico
Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
11.5.3.2.1. Inflammatory
bowel disease
11.5.3.2.2. Diabetes
11.5.3.2.3. Ulcerative
colitis and Crohn disease
11.5.3.2.4. Acromegaly
and neuroendocrine tumors
11.5.3.2.5. Osteoporosis
11.5.3.2.6. Inflammatory
disease
11.5.3.2.7. Others
11.5.3.3. Mexico
Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
11.5.3.3.1. Hospital
Pharmacies
11.5.3.3.2. Retail
Pharmacies
11.5.3.3.3. Online
11.5.3.3.4. Others
11.5.4. Rest of
North America
11.5.4.1. Rest
of North America Oral Biologics Market Revenue (US$ Mn) and Forecasts, By
Offering
11.5.4.1.1. Glucagon-like
Peptide 1 (GLP-1) Receptor Agonist
11.5.4.1.2. Hormone
11.5.4.1.3. Recombinant
Enzyme
11.5.4.1.4. Guanylate
Cyclase-C Agonist
11.5.4.1.5. Somatostatin
Analogue
11.5.4.1.6. Combination
Drugs
11.5.4.1.7. Others
11.5.4.2. Rest
of North America Oral Biologics Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Area
11.5.4.2.1. Inflammatory
bowel disease
11.5.4.2.2. Diabetes
11.5.4.2.3. Ulcerative
colitis and Crohn disease
11.5.4.2.4. Acromegaly
and neuroendocrine tumors
11.5.4.2.5. Osteoporosis
11.5.4.2.6. Inflammatory
disease
11.5.4.2.7. Others
11.5.4.3. Rest
of North America Oral Biologics Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
11.5.4.3.1. Hospital
Pharmacies
11.5.4.3.2. Retail
Pharmacies
11.5.4.3.3. Online
11.5.4.3.4. Others
11.6. Key
Segment for Channeling Investments
11.6.1. By
Country
11.6.2. By
Offering
11.6.3. By
Therapeutic Area
11.6.4. By
Distribution Channel
12. Europe
Oral Biologics Market Analysis and Forecasts, 2020 - 2028
12.1. Overview
12.1.1. Europe
Oral Biologics Market Revenue (US$ Mn)
12.2. Europe
Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Offering
12.2.1. Glucagon-like
Peptide 1 (GLP-1) Receptor Agonist
12.2.2. Hormone
12.2.3. Recombinant
Enzyme
12.2.4. Guanylate
Cyclase-C Agonist
12.2.5. Somatostatin
Analogue
12.2.6. Combination
Drugs
12.2.7. Others
12.3. Europe
Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
12.3.1. Inflammatory
bowel disease
12.3.2. Diabetes
12.3.3. Ulcerative
colitis and Crohn disease
12.3.4. Acromegaly
and neuroendocrine tumors
12.3.5. Osteoporosis
12.3.6. Inflammatory
disease
12.3.7. Others
12.4. Europe
Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
12.4.1. Hospital
Pharmacies
12.4.2. Retail
Pharmacies
12.4.3. Online
12.4.4. Others
12.5. Europe
Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Country
12.5.1. France
12.5.1.1. France
Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Offering
12.5.1.1.1. Glucagon-like
Peptide 1 (GLP-1) Receptor Agonist
12.5.1.1.2. Hormone
12.5.1.1.3. Recombinant
Enzyme
12.5.1.1.4. Guanylate
Cyclase-C Agonist
12.5.1.1.5. Somatostatin
Analogue
12.5.1.1.6. Combination
Drugs
12.5.1.1.7. Others
12.5.1.2. France
Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
12.5.1.2.1. Inflammatory
bowel disease
12.5.1.2.2. Diabetes
12.5.1.2.3. Ulcerative
colitis and Crohn disease
12.5.1.2.4. Acromegaly
and neuroendocrine tumors
12.5.1.2.5. Osteoporosis
12.5.1.2.6. Inflammatory
disease
12.5.1.2.7. Others
12.5.1.3. France
Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
12.5.1.3.1. Hospital
Pharmacies
12.5.1.3.2. Retail
Pharmacies
12.5.1.3.3. Online
12.5.1.3.4. Others
12.5.2. The UK
12.5.2.1. The
UK Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Offering
12.5.2.1.1. Glucagon-like
Peptide 1 (GLP-1) Receptor Agonist
12.5.2.1.2. Hormone
12.5.2.1.3. Recombinant
Enzyme
12.5.2.1.4. Guanylate
Cyclase-C Agonist
12.5.2.1.5. Somatostatin
Analogue
12.5.2.1.6. Combination
Drugs
12.5.2.1.7. Others
12.5.2.2. The
UK Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
12.5.2.2.1. Inflammatory
bowel disease
12.5.2.2.2. Diabetes
12.5.2.2.3. Ulcerative
colitis and Crohn disease
12.5.2.2.4. Acromegaly
and neuroendocrine tumors
12.5.2.2.5. Osteoporosis
12.5.2.2.6. Inflammatory
disease
12.5.2.2.7. Others
12.5.2.3. The UK
Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
12.5.2.3.1. Hospital
Pharmacies
12.5.2.3.2. Retail
Pharmacies
12.5.2.3.3. Online
12.5.2.3.4. Others
12.5.3. Spain
12.5.3.1. Spain
Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Offering
12.5.3.1.1. Glucagon-like
Peptide 1 (GLP-1) Receptor Agonist
12.5.3.1.2. Hormone
12.5.3.1.3. Recombinant
Enzyme
12.5.3.1.4. Guanylate
Cyclase-C Agonist
12.5.3.1.5. Somatostatin
Analogue
12.5.3.1.6. Combination
Drugs
12.5.3.1.7. Others
12.5.3.2. Spain
Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
12.5.3.2.1. Inflammatory
bowel disease
12.5.3.2.2. Diabetes
12.5.3.2.3. Ulcerative
colitis and Crohn disease
12.5.3.2.4. Acromegaly
and neuroendocrine tumors
12.5.3.2.5. Osteoporosis
12.5.3.2.6. Inflammatory
disease
12.5.3.2.7. Others
12.5.3.3. Spain
Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
12.5.3.3.1. Hospital
Pharmacies
12.5.3.3.2. Retail
Pharmacies
12.5.3.3.3. Online
12.5.3.3.4. Others
12.5.4. Germany
12.5.4.1. Germany
Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Offering
12.5.4.1.1. Glucagon-like
Peptide 1 (GLP-1) Receptor Agonist
12.5.4.1.2. Hormone
12.5.4.1.3. Recombinant
Enzyme
12.5.4.1.4. Guanylate
Cyclase-C Agonist
12.5.4.1.5. Somatostatin
Analogue
12.5.4.1.6. Combination
Drugs
12.5.4.1.7. Others
12.5.4.2. Germany
Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
12.5.4.2.1. Inflammatory
bowel disease
12.5.4.2.2. Diabetes
12.5.4.2.3. Ulcerative
colitis and Crohn disease
12.5.4.2.4. Acromegaly
and neuroendocrine tumors
12.5.4.2.5. Osteoporosis
12.5.4.2.6. Inflammatory
disease
12.5.4.2.7. Others
12.5.4.3. Germany
Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
12.5.4.3.1. Hospital
Pharmacies
12.5.4.3.2. Retail
Pharmacies
12.5.4.3.3. Online
12.5.4.3.4. Others
12.5.5. Italy
12.5.5.1. Italy
Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Offering
12.5.5.1.1. Glucagon-like
Peptide 1 (GLP-1) Receptor Agonist
12.5.5.1.2. Hormone
12.5.5.1.3. Recombinant
Enzyme
12.5.5.1.4. Guanylate
Cyclase-C Agonist
12.5.5.1.5. Somatostatin
Analogue
12.5.5.1.6. Combination
Drugs
12.5.5.1.7. Others
12.5.5.2. Italy
Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
12.5.5.2.1. Inflammatory
bowel disease
12.5.5.2.2. Diabetes
12.5.5.2.3. Ulcerative
colitis and Crohn disease
12.5.5.2.4. Acromegaly
and neuroendocrine tumors
12.5.5.2.5. Osteoporosis
12.5.5.2.6. Inflammatory
disease
12.5.5.2.7. Others
12.5.5.3. Italy
Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
12.5.5.3.1. Hospital
Pharmacies
12.5.5.3.2. Retail
Pharmacies
12.5.5.3.3. Online
12.5.5.3.4. Others
12.5.6. Nordic
Countries
12.5.6.1. Nordic
Countries Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Offering
12.5.6.1.1. Glucagon-like
Peptide 1 (GLP-1) Receptor Agonist
12.5.6.1.2. Hormone
12.5.6.1.3. Recombinant
Enzyme
12.5.6.1.4. Guanylate
Cyclase-C Agonist
12.5.6.1.5. Somatostatin
Analogue
12.5.6.1.6. Combination
Drugs
12.5.6.1.7. Others
12.5.6.2. Nordic
Countries Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Therapeutic
Area
12.5.6.2.1. Inflammatory
bowel disease
12.5.6.2.2. Diabetes
12.5.6.2.3. Ulcerative
colitis and Crohn disease
12.5.6.2.4. Acromegaly
and neuroendocrine tumors
12.5.6.2.5. Osteoporosis
12.5.6.2.6. Inflammatory
disease
12.5.6.2.7. Others
12.5.6.3. Nordic
Countries Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
12.5.6.3.1. Hospital
Pharmacies
12.5.6.3.2. Retail
Pharmacies
12.5.6.3.3. Online
12.5.6.3.4. Others
12.5.6.4. Nordic
Countries Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Country
12.5.6.4.1. Denmark
12.5.6.4.2. Finland
12.5.6.4.3. Iceland
12.5.6.4.4. Sweden
12.5.6.4.5. Norway
12.5.7. Benelux
Union
12.5.7.1. Benelux
Union Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Offering
12.5.7.1.1. Glucagon-like
Peptide 1 (GLP-1) Receptor Agonist
12.5.7.1.2. Hormone
12.5.7.1.3. Recombinant
Enzyme
12.5.7.1.4. Guanylate
Cyclase-C Agonist
12.5.7.1.5. Somatostatin
Analogue
12.5.7.1.6. Combination
Drugs
12.5.7.1.7. Others
12.5.7.2. Benelux
Union Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
12.5.7.2.1. Inflammatory
bowel disease
12.5.7.2.2. Diabetes
12.5.7.2.3. Ulcerative
colitis and Crohn disease
12.5.7.2.4. Acromegaly
and neuroendocrine tumors
12.5.7.2.5. Osteoporosis
12.5.7.2.6. Inflammatory
disease
12.5.7.2.7. Others
12.5.7.3. Benelux
Union Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
12.5.7.3.1. Hospital
Pharmacies
12.5.7.3.2. Retail
Pharmacies
12.5.7.3.3. Online
12.5.7.3.4. Others
12.5.7.4. Benelux
Union Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Country
12.5.7.4.1. Belgium
12.5.7.4.2. The
Netherlands
12.5.7.4.3. Luxembourg
12.5.8. Rest of
Europe
12.5.8.1. Rest
of Europe Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Offering
12.5.8.1.1. Glucagon-like
Peptide 1 (GLP-1) Receptor Agonist
12.5.8.1.2. Hormone
12.5.8.1.3. Recombinant
Enzyme
12.5.8.1.4. Guanylate
Cyclase-C Agonist
12.5.8.1.5. Somatostatin
Analogue
12.5.8.1.6. Combination
Drugs
12.5.8.1.7. Others
12.5.8.2. Rest
of Europe Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Therapeutic
Area
12.5.8.2.1. Inflammatory
bowel disease
12.5.8.2.2. Diabetes
12.5.8.2.3. Ulcerative
colitis and Crohn disease
12.5.8.2.4. Acromegaly
and neuroendocrine tumors
12.5.8.2.5. Osteoporosis
12.5.8.2.6. Inflammatory
disease
12.5.8.2.7. Others
12.5.8.3. Rest
of Europe Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
12.5.8.3.1. Hospital
Pharmacies
12.5.8.3.2. Retail
Pharmacies
12.5.8.3.3. Online
12.5.8.3.4. Others
12.6. Key
Segment for Channeling Investments
12.6.1. By
Country
12.6.2. By
Offering
12.6.3. By
Therapeutic Area
12.6.4. By
Distribution Channel
13. Asia
Pacific Oral Biologics Market Analysis and Forecasts, 2020 - 2028
13.1. Overview
13.1.1. Asia
Pacific Oral Biologics Market Revenue (US$ Mn)
13.2. Asia
Pacific Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Offering
13.2.1. Glucagon-like
Peptide 1 (GLP-1) Receptor Agonist
13.2.2. Hormone
13.2.3. Recombinant
Enzyme
13.2.4. Guanylate
Cyclase-C Agonist
13.2.5. Somatostatin
Analogue
13.2.6. Combination
Drugs
13.2.7. Others
13.3. Asia
Pacific Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Therapeutic
Area
13.3.1. Inflammatory
bowel disease
13.3.2. Diabetes
13.3.3. Ulcerative
colitis and Crohn disease
13.3.4. Acromegaly
and neuroendocrine tumors
13.3.5. Osteoporosis
13.3.6. Inflammatory
disease
13.3.7. Others
13.4. Asia
Pacific Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
13.4.1. Hospital
Pharmacies
13.4.2. Retail
Pharmacies
13.4.3. Online
13.4.4. Others
13.5. Asia
Pacific Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Country
13.5.1. China
13.5.1.1. China
Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Offering
13.5.1.1.1. Glucagon-like
Peptide 1 (GLP-1) Receptor Agonist
13.5.1.1.2. Hormone
13.5.1.1.3. Recombinant
Enzyme
13.5.1.1.4. Guanylate
Cyclase-C Agonist
13.5.1.1.5. Somatostatin
Analogue
13.5.1.1.6. Combination
Drugs
13.5.1.1.7. Others
13.5.1.2. China
Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
13.5.1.2.1. Inflammatory
bowel disease
13.5.1.2.2. Diabetes
13.5.1.2.3. Ulcerative
colitis and Crohn disease
13.5.1.2.4. Acromegaly
and neuroendocrine tumors
13.5.1.2.5. Osteoporosis
13.5.1.2.6. Inflammatory
disease
13.5.1.2.7. Others
13.5.1.3. China
Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
13.5.1.3.1. Hospital
Pharmacies
13.5.1.3.2. Retail
Pharmacies
13.5.1.3.3. Online
13.5.1.3.4. Others
13.5.2. Japan
13.5.2.1. Japan
Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Offering
13.5.2.1.1. Glucagon-like
Peptide 1 (GLP-1) Receptor Agonist
13.5.2.1.2. Hormone
13.5.2.1.3. Recombinant
Enzyme
13.5.2.1.4. Guanylate
Cyclase-C Agonist
13.5.2.1.5. Somatostatin
Analogue
13.5.2.1.6. Combination
Drugs
13.5.2.1.7. Others
13.5.2.2. Japan
Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
13.5.2.2.1. Inflammatory
bowel disease
13.5.2.2.2. Diabetes
13.5.2.2.3. Ulcerative
colitis and Crohn disease
13.5.2.2.4. Acromegaly
and neuroendocrine tumors
13.5.2.2.5. Osteoporosis
13.5.2.2.6. Inflammatory
disease
13.5.2.2.7. Others
13.5.2.3. Japan
Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
13.5.2.3.1. Hospital
Pharmacies
13.5.2.3.2. Retail
Pharmacies
13.5.2.3.3. Online
13.5.2.3.4. Others
13.5.3. India
13.5.3.1. India
Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Offering
13.5.3.1.1. Glucagon-like
Peptide 1 (GLP-1) Receptor Agonist
13.5.3.1.2. Hormone
13.5.3.1.3. Recombinant
Enzyme
13.5.3.1.4. Guanylate
Cyclase-C Agonist
13.5.3.1.5. Somatostatin
Analogue
13.5.3.1.6. Combination
Drugs
13.5.3.1.7. Others
13.5.3.2. India
Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
13.5.3.2.1. Inflammatory
bowel disease
13.5.3.2.2. Diabetes
13.5.3.2.3. Ulcerative
colitis and Crohn disease
13.5.3.2.4. Acromegaly
and neuroendocrine tumors
13.5.3.2.5. Osteoporosis
13.5.3.2.6. Inflammatory
disease
13.5.3.2.7. Others
13.5.3.3. India
Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
13.5.3.3.1. Hospital
Pharmacies
13.5.3.3.2. Retail
Pharmacies
13.5.3.3.3. Online
13.5.3.3.4. Others
13.5.4. New
Zealand
13.5.4.1. New
Zealand Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Offering
13.5.4.1.1. Glucagon-like
Peptide 1 (GLP-1) Receptor Agonist
13.5.4.1.2. Hormone
13.5.4.1.3. Recombinant
Enzyme
13.5.4.1.4. Guanylate
Cyclase-C Agonist
13.5.4.1.5. Somatostatin
Analogue
13.5.4.1.6. Combination
Drugs
13.5.4.1.7. Others
13.5.4.2. New
Zealand Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Therapeutic
Area
13.5.4.2.1. Inflammatory
bowel disease
13.5.4.2.2. Diabetes
13.5.4.2.3. Ulcerative
colitis and Crohn disease
13.5.4.2.4. Acromegaly
and neuroendocrine tumors
13.5.4.2.5. Osteoporosis
13.5.4.2.6. Inflammatory
disease
13.5.4.2.7. Others
13.5.4.3. New
Zealand Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
13.5.4.3.1. Hospital
Pharmacies
13.5.4.3.2. Retail
Pharmacies
13.5.4.3.3. Online
13.5.4.3.4. Others
13.5.5. Australia
13.5.5.1. Australia
Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Offering
13.5.5.1.1. Glucagon-like
Peptide 1 (GLP-1) Receptor Agonist
13.5.5.1.2. Hormone
13.5.5.1.3. Recombinant
Enzyme
13.5.5.1.4. Guanylate
Cyclase-C Agonist
13.5.5.1.5. Somatostatin
Analogue
13.5.5.1.6. Combination
Drugs
13.5.5.1.7. Others
13.5.5.2. Australia
Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
13.5.5.2.1. Inflammatory
bowel disease
13.5.5.2.2. Diabetes
13.5.5.2.3. Ulcerative
colitis and Crohn disease
13.5.5.2.4. Acromegaly
and neuroendocrine tumors
13.5.5.2.5. Osteoporosis
13.5.5.2.6. Inflammatory
disease
13.5.5.2.7. Others
13.5.5.3. Australia
Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
13.5.5.3.1. Hospital
Pharmacies
13.5.5.3.2. Retail
Pharmacies
13.5.5.3.3. Online
13.5.5.3.4. Others
13.5.6. South
Korea
13.5.6.1. South
Korea Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Offering
13.5.6.1.1. Glucagon-like
Peptide 1 (GLP-1) Receptor Agonist
13.5.6.1.2. Hormone
13.5.6.1.3. Recombinant
Enzyme
13.5.6.1.4. Guanylate
Cyclase-C Agonist
13.5.6.1.5. Somatostatin
Analogue
13.5.6.1.6. Combination
Drugs
13.5.6.1.7. Others
13.5.6.2. South
Korea Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
13.5.6.2.1. Inflammatory
bowel disease
13.5.6.2.2. Diabetes
13.5.6.2.3. Ulcerative
colitis and Crohn disease
13.5.6.2.4. Acromegaly
and neuroendocrine tumors
13.5.6.2.5. Osteoporosis
13.5.6.2.6. Inflammatory
disease
13.5.6.2.7. Others
13.5.6.3. South
Korea Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
13.5.6.3.1. Hospital
Pharmacies
13.5.6.3.2. Retail
Pharmacies
13.5.6.3.3. Online
13.5.6.3.4. Others
13.5.7. Southeast
Asia
13.5.7.1. Southeast
Asia Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Offering
13.5.7.1.1. Glucagon-like
Peptide 1 (GLP-1) Receptor Agonist
13.5.7.1.2. Hormone
13.5.7.1.3. Recombinant
Enzyme
13.5.7.1.4. Guanylate
Cyclase-C Agonist
13.5.7.1.5. Somatostatin
Analogue
13.5.7.1.6. Combination
Drugs
13.5.7.1.7. Others
13.5.7.2. Southeast
Asia Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
13.5.7.2.1. Inflammatory
bowel disease
13.5.7.2.2. Diabetes
13.5.7.2.3. Ulcerative
colitis and Crohn disease
13.5.7.2.4. Acromegaly
and neuroendocrine tumors
13.5.7.2.5. Osteoporosis
13.5.7.2.6. Inflammatory
disease
13.5.7.2.7. Others
13.5.7.3. Southeast
Asia Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
13.5.7.3.1. Hospital
Pharmacies
13.5.7.3.2. Retail
Pharmacies
13.5.7.3.3. Online
13.5.7.3.4. Others
13.5.7.4. Southeast
Asia Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Country
13.5.7.4.1. Indonesia
13.5.7.4.2. Thailand
13.5.7.4.3. Malaysia
13.5.7.4.4. Singapore
13.5.7.4.5. Rest
of Southeast Asia
13.5.8. Rest of
Asia Pacific
13.5.8.1. Rest
of Asia Pacific Oral Biologics Market Revenue (US$ Mn) and Forecasts, By
Offering
13.5.8.1.1. Glucagon-like
Peptide 1 (GLP-1) Receptor Agonist
13.5.8.1.2. Hormone
13.5.8.1.3. Recombinant
Enzyme
13.5.8.1.4. Guanylate
Cyclase-C Agonist
13.5.8.1.5. Somatostatin
Analogue
13.5.8.1.6. Combination
Drugs
13.5.8.1.7. Others
13.5.8.2. Rest
of Asia Pacific Oral Biologics Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Area
13.5.8.2.1. Inflammatory
bowel disease
13.5.8.2.2. Diabetes
13.5.8.2.3. Ulcerative
colitis and Crohn disease
13.5.8.2.4. Acromegaly
and neuroendocrine tumors
13.5.8.2.5. Osteoporosis
13.5.8.2.6. Inflammatory
disease
13.5.8.2.7. Others
13.5.8.3. Rest
of Asia Pacific Oral Biologics Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
13.5.8.3.1. Hospital
Pharmacies
13.5.8.3.2. Retail
Pharmacies
13.5.8.3.3. Online
13.5.8.3.4. Others
13.6. Key
Segment for Channeling Investments
13.6.1. By
Country
13.6.2. By
Offering
13.6.3. By
Therapeutic Area
13.6.4. By
Distribution Channel
14. Middle
East and Africa Oral Biologics Market Analysis and Forecasts, 2020 - 2028
14.1. Overview
14.1.1. Middle
East and Africa Oral Biologics Market Revenue (US$ Mn)
14.2. Middle
East and Africa Oral Biologics Market Revenue (US$ Mn) and Forecasts, By
Offering
14.2.1. Glucagon-like
Peptide 1 (GLP-1) Receptor Agonist
14.2.2. Hormone
14.2.3. Recombinant
Enzyme
14.2.4. Guanylate
Cyclase-C Agonist
14.2.5. Somatostatin
Analogue
14.2.6. Combination
Drugs
14.2.7. Others
14.3. Middle
East and Africa Oral Biologics Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Area
14.3.1. Inflammatory
bowel disease
14.3.2. Diabetes
14.3.3. Ulcerative
colitis and Crohn disease
14.3.4. Acromegaly
and neuroendocrine tumors
14.3.5. Osteoporosis
14.3.6. Inflammatory
disease
14.3.7. Others
14.4. Middle
East and Africa Oral Biologics Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
14.4.1. Hospital
Pharmacies
14.4.2. Retail
Pharmacies
14.4.3. Online
14.4.4. Others
14.5. Middle
East and Africa Oral Biologics Market Revenue (US$ Mn) and Forecasts, By
Country
14.5.1. Saudi
Arabia
14.5.1.1. Saudi
Arabia Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Offering
14.5.1.1.1. Glucagon-like
Peptide 1 (GLP-1) Receptor Agonist
14.5.1.1.2. Hormone
14.5.1.1.3. Recombinant
Enzyme
14.5.1.1.4. Guanylate
Cyclase-C Agonist
14.5.1.1.5. Somatostatin
Analogue
14.5.1.1.6. Combination
Drugs
14.5.1.1.7. Others
14.5.1.2. Saudi
Arabia Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Therapeutic
Area
14.5.1.2.1. Inflammatory
bowel disease
14.5.1.2.2. Diabetes
14.5.1.2.3. Ulcerative
colitis and Crohn disease
14.5.1.2.4. Acromegaly
and neuroendocrine tumors
14.5.1.2.5. Osteoporosis
14.5.1.2.6. Inflammatory
disease
14.5.1.2.7. Others
14.5.1.3. Saudi
Arabia Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
14.5.1.3.1. Hospital
Pharmacies
14.5.1.3.2. Retail
Pharmacies
14.5.1.3.3. Online
14.5.1.3.4. Others
14.5.2. UAE
14.5.2.1. UAE
Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Offering
14.5.2.1.1. Glucagon-like
Peptide 1 (GLP-1) Receptor Agonist
14.5.2.1.2. Hormone
14.5.2.1.3. Recombinant
Enzyme
14.5.2.1.4. Guanylate
Cyclase-C Agonist
14.5.2.1.5. Somatostatin
Analogue
14.5.2.1.6. Combination
Drugs
14.5.2.1.7. Others
14.5.2.2. UAE
Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
14.5.2.2.1. Inflammatory
bowel disease
14.5.2.2.2. Diabetes
14.5.2.2.3. Ulcerative
colitis and Crohn disease
14.5.2.2.4. Acromegaly
and neuroendocrine tumors
14.5.2.2.5. Osteoporosis
14.5.2.2.6. Inflammatory
disease
14.5.2.2.7. Others
14.5.2.3. UAE
Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
14.5.2.3.1. Hospital
Pharmacies
14.5.2.3.2. Retail
Pharmacies
14.5.2.3.3. Online
14.5.2.3.4. Others
14.5.3. Egypt
14.5.3.1. Egypt
Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Offering
14.5.3.1.1. Glucagon-like
Peptide 1 (GLP-1) Receptor Agonist
14.5.3.1.2. Hormone
14.5.3.1.3. Recombinant
Enzyme
14.5.3.1.4. Guanylate
Cyclase-C Agonist
14.5.3.1.5. Somatostatin
Analogue
14.5.3.1.6. Combination
Drugs
14.5.3.1.7. Others
14.5.3.2. Egypt
Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
14.5.3.2.1. Inflammatory
bowel disease
14.5.3.2.2. Diabetes
14.5.3.2.3. Ulcerative
colitis and Crohn disease
14.5.3.2.4. Acromegaly
and neuroendocrine tumors
14.5.3.2.5. Osteoporosis
14.5.3.2.6. Inflammatory
disease
14.5.3.2.7. Others
14.5.3.3. Egypt
Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
14.5.3.3.1. Hospital
Pharmacies
14.5.3.3.2. Retail
Pharmacies
14.5.3.3.3. Online
14.5.3.3.4. Others
14.5.4. Kuwait
14.5.4.1. Kuwait
Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Offering
14.5.4.1.1. Glucagon-like
Peptide 1 (GLP-1) Receptor Agonist
14.5.4.1.2. Hormone
14.5.4.1.3. Recombinant
Enzyme
14.5.4.1.4. Guanylate
Cyclase-C Agonist
14.5.4.1.5. Somatostatin
Analogue
14.5.4.1.6. Combination
Drugs
14.5.4.1.7. Others
14.5.4.2. Kuwait
Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
14.5.4.2.1. Inflammatory
bowel disease
14.5.4.2.2. Diabetes
14.5.4.2.3. Ulcerative
colitis and Crohn disease
14.5.4.2.4. Acromegaly
and neuroendocrine tumors
14.5.4.2.5. Osteoporosis
14.5.4.2.6. Inflammatory
disease
14.5.4.2.7. Others
14.5.4.3. Kuwait
Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
14.5.4.3.1. Hospital
Pharmacies
14.5.4.3.2. Retail
Pharmacies
14.5.4.3.3. Online
14.5.4.3.4. Others
14.5.5. South
Africa
14.5.5.1. South
Africa Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Offering
14.5.5.1.1. Glucagon-like
Peptide 1 (GLP-1) Receptor Agonist
14.5.5.1.2. Hormone
14.5.5.1.3. Recombinant
Enzyme
14.5.5.1.4. Guanylate
Cyclase-C Agonist
14.5.5.1.5. Somatostatin
Analogue
14.5.5.1.6. Combination
Drugs
14.5.5.1.7. Others
14.5.5.2. South
Africa Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Therapeutic
Area
14.5.5.2.1. Inflammatory
bowel disease
14.5.5.2.2. Diabetes
14.5.5.2.3. Ulcerative
colitis and Crohn disease
14.5.5.2.4. Acromegaly
and neuroendocrine tumors
14.5.5.2.5. Osteoporosis
14.5.5.2.6. Inflammatory
disease
14.5.5.2.7. Others
14.5.5.3. South
Africa Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
14.5.5.3.1. Hospital
Pharmacies
14.5.5.3.2. Retail
Pharmacies
14.5.5.3.3. Online
14.5.5.3.4. Others
14.5.6. Rest of
Middle East & Africa
14.5.6.1. Rest
of Middle East & Africa Oral Biologics Market Revenue (US$ Mn) and
Forecasts, By Offering
14.5.6.1.1. Glucagon-like
Peptide 1 (GLP-1) Receptor Agonist
14.5.6.1.2. Hormone
14.5.6.1.3. Recombinant
Enzyme
14.5.6.1.4. Guanylate
Cyclase-C Agonist
14.5.6.1.5. Somatostatin
Analogue
14.5.6.1.6. Combination
Drugs
14.5.6.1.7. Others
14.5.6.2. Rest
of Middle East & Africa Oral Biologics Market Revenue (US$ Mn) and
Forecasts, By Therapeutic Area
14.5.6.2.1. Inflammatory
bowel disease
14.5.6.2.2. Diabetes
14.5.6.2.3. Ulcerative
colitis and Crohn disease
14.5.6.2.4. Acromegaly
and neuroendocrine tumors
14.5.6.2.5. Osteoporosis
14.5.6.2.6. Inflammatory
disease
14.5.6.2.7. Others
14.5.6.3. Rest
of Middle East & Africa Oral Biologics Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
14.5.6.3.1. Hospital
Pharmacies
14.5.6.3.2. Retail
Pharmacies
14.5.6.3.3. Online
14.5.6.3.4. Others
14.6. Key
Segment for Channeling Investments
14.6.1. By
Country
14.6.2. By
Offering
14.6.3. By
Therapeutic Area
14.6.4. By
Distribution Channel
15. Latin
America Oral Biologics Market Analysis and Forecasts, 2020 - 2028
15.1. Overview
15.1.1. Latin
America Oral Biologics Market Revenue (US$ Mn)
15.2. Latin
America Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Offering
15.2.1. Glucagon-like
Peptide 1 (GLP-1) Receptor Agonist
15.2.2. Hormone
15.2.3. Recombinant
Enzyme
15.2.4. Guanylate
Cyclase-C Agonist
15.2.5. Somatostatin
Analogue
15.2.6. Combination
Drugs
15.2.7. Others
15.3. Latin
America Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Therapeutic
Area
15.3.1. Inflammatory
bowel disease
15.3.2. Diabetes
15.3.3. Ulcerative
colitis and Crohn disease
15.3.4. Acromegaly
and neuroendocrine tumors
15.3.5. Osteoporosis
15.3.6. Inflammatory
disease
15.3.7. Others
15.4. Latin
America Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
15.4.1. Hospital
Pharmacies
15.4.2. Retail
Pharmacies
15.4.3. Online
15.4.4. Others
15.5. Latin
America Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Country
15.5.1. Brazil
15.5.1.1. Brazil
Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Offering
15.5.1.1.1. Glucagon-like
Peptide 1 (GLP-1) Receptor Agonist
15.5.1.1.2. Hormone
15.5.1.1.3. Recombinant
Enzyme
15.5.1.1.4. Guanylate
Cyclase-C Agonist
15.5.1.1.5. Somatostatin
Analogue
15.5.1.1.6. Combination
Drugs
15.5.1.1.7. Others
15.5.1.2. Brazil
Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
15.5.1.2.1. Inflammatory
bowel disease
15.5.1.2.2. Diabetes
15.5.1.2.3. Ulcerative
colitis and Crohn disease
15.5.1.2.4. Acromegaly
and neuroendocrine tumors
15.5.1.2.5. Osteoporosis
15.5.1.2.6. Inflammatory
disease
15.5.1.2.7. Others
15.5.1.3. Brazil
Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
15.5.1.3.1. Hospital
Pharmacies
15.5.1.3.2. Retail
Pharmacies
15.5.1.3.3. Online
15.5.1.3.4. Others
15.5.2. Argentina
15.5.2.1. Argentina
Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Offering
15.5.2.1.1. Glucagon-like
Peptide 1 (GLP-1) Receptor Agonist
15.5.2.1.2. Hormone
15.5.2.1.3. Recombinant
Enzyme
15.5.2.1.4. Guanylate
Cyclase-C Agonist
15.5.2.1.5. Somatostatin
Analogue
15.5.2.1.6. Combination
Drugs
15.5.2.1.7. Others
15.5.2.2. Argentina
Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
15.5.2.2.1. Inflammatory
bowel disease
15.5.2.2.2. Diabetes
15.5.2.2.3. Ulcerative
colitis and Crohn disease
15.5.2.2.4. Acromegaly
and neuroendocrine tumors
15.5.2.2.5. Osteoporosis
15.5.2.2.6. Inflammatory
disease
15.5.2.2.7. Others
15.5.2.3. Argentina
Oral Biologics Market Revenue (US$ Mn) and Forecasts, By Distribution Channel
15.5.2.3.1. Hospital
Pharmacies
15.5.2.3.2. Retail
Pharmacies
15.5.2.3.3. Online
15.5.2.3.4. Others
15.5.3. Rest of
Latin America
15.5.3.1. Rest
of Latin America Oral Biologics Market Revenue (US$ Mn) and Forecasts, By
Offering
15.5.3.1.1. Glucagon-like
Peptide 1 (GLP-1) Receptor Agonist
15.5.3.1.2. Hormone
15.5.3.1.3. Recombinant
Enzyme
15.5.3.1.4. Guanylate
Cyclase-C Agonist
15.5.3.1.5. Somatostatin
Analogue
15.5.3.1.6. Combination
Drugs
15.5.3.1.7. Others
15.5.3.2. Rest
of Latin America Oral Biologics Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Area
15.5.3.2.1. Inflammatory
bowel disease
15.5.3.2.2. Diabetes
15.5.3.2.3. Ulcerative
colitis and Crohn disease
15.5.3.2.4. Acromegaly
and neuroendocrine tumors
15.5.3.2.5. Osteoporosis
15.5.3.2.6. Inflammatory
disease
15.5.3.2.7. Others
15.5.3.3. Rest
of Latin America Oral Biologics Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
15.5.3.3.1. Hospital
Pharmacies
15.5.3.3.2. Retail
Pharmacies
15.5.3.3.3. Online
15.5.3.3.4. Others
15.6. Key
Segment for Channeling Investments
15.6.1. By
Country
15.6.2. By
Offering
15.6.3. By
Therapeutic Area
15.6.4. By
Distribution Channel
16. Competitive
Benchmarking
16.1. Market
Share Analysis, 2019
16.2. Global
Presence and Growth Strategies
16.2.1. Mergers
and Acquisitions
16.2.2. Product
Launches
16.2.3. Investments
Trends
16.2.4. R&D
Initiatives
17. Player
Profiles
17.1. AbbVie
Inc.
17.1.1. Company
Details
17.1.2. Company
Overview
17.1.3. Product
Offerings
17.1.4. Key
Developments
17.1.5. Financial
Analysis
17.1.6. SWOT
Analysis
17.1.7. Business
Strategies
17.2. Allena
Pharmaceuticals, Inc.
17.2.1. Company
Details
17.2.2. Company
Overview
17.2.3. Product
Offerings
17.2.4. Key Developments
17.2.5. Financial
Analysis
17.2.6. SWOT
Analysis
17.2.7. Business
Strategies
17.3. Gilead
Sciences, Inc.
17.3.1. Company
Details
17.3.2. Company
Overview
17.3.3. Product
Offerings
17.3.4. Key
Developments
17.3.5. Financial
Analysis
17.3.6. SWOT
Analysis
17.3.7. Business
Strategies
17.4. McKesson
Corporation
17.4.1. Company
Details
17.4.2. Company
Overview
17.4.3. Product
Offerings
17.4.4. Key
Developments
17.4.5. Financial
Analysis
17.4.6. SWOT
Analysis
17.4.7. Business
Strategies
17.5. Novo
Nordisk A/S
17.5.1. Company
Details
17.5.2. Company
Overview
17.5.3. Product
Offerings
17.5.4. Key
Developments
17.5.5. Financial
Analysis
17.5.6. SWOT
Analysis
17.5.7. Business
Strategies
17.6. Intertek
Group plc
17.6.1. Company
Details
17.6.2. Company
Overview
17.6.3. Product
Offerings
17.6.4. Key
Developments
17.6.5. Financial
Analysis
17.6.6. SWOT
Analysis
17.6.7. Business
Strategies
17.7. Pfizer
Inc
17.7.1. Company
Details
17.7.2. Company
Overview
17.7.3. Product
Offerings
17.7.4. Key
Developments
17.7.5. Financial
Analysis
17.7.6. SWOT
Analysis
17.7.7. Business
Strategies
17.8. Rani Therapeutics
17.8.1. Company
Details
17.8.2. Company
Overview
17.8.3. Product
Offerings
17.8.4. Key
Developments
17.8.5. Financial
Analysis
17.8.6. SWOT
Analysis
17.8.7. Business
Strategies
17.9. Veloce
Digital Health
17.9.1. Company
Details
17.9.2. Company
Overview
17.9.3. Product
Offerings
17.9.4. Key
Developments
17.9.5. Financial
Analysis
17.9.6. SWOT
Analysis
17.9.7. Business Strategies
17.10. Other
Industry Participants
18. Key
Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User and
Enterprise User
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
